https://www.globenewswire.com/fr/news-release/2021/10/25/2319699/33525/en/FibroGen-Announces-Analyses-from-Roxadustat-Global-Phase-3-Program-at-American-Society-of-Nephrology-Kidney-Week-2021.html
FibroGen Announces Analyses from Roxadustat Global Phase 3
SAN FRANCISCO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that analyses from the global Phase 3 roxadustat clinical...
announcesanalysesroxadustatglobalphase
https://www.fiercebiotech.com/research/hypoxia-boosts-fetal-hemoglobin-red-blood-cells
AZ, FibroGen's roxadustat holds promise for sickle cell disease
Oct 18, 2022 - The finding opens the door to the use of proline hydroxylase inhibitors to treat beta thalassemia and sickle cell disease.
sickle cellazroxadustatholdspromise
https://www.globenewswire.com/fr/news-release/2017/10/18/1149112/33525/en/FibroGen-Announces-Acceptance-by-China-FDA-of-Roxadustat-New-Drug-Application-NDA-for-Treatment-of-Anemia-Associated-With-Dialysis-and-Non-Dialysis-Chronic-Kidney-Disease-CKD.html
FibroGen Announces Acceptance by China FDA of Roxadustat
Triggers Milestone Payment of $15 Million by AstraZeneca ...
by chinaannouncesacceptancefdaroxadustat
https://www.prnewswire.com/news-releases/european-medicines-agency-accepts-astellas-marketing-authorization-application-for-roxadustat-301063148.html
European Medicines Agency Accepts Astellas' Marketing Authorization Application for Roxadustat
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique...
european medicines agencyacceptsastellasmarketingauthorization
https://www.biospace.com/fibrogen-announces-results-for-matterhorn-a-phase-3-clinical-study-of-roxadustat-for-the-treatment-of-anemia-in-patients-with-myelodysplastic-syndromes-mds-study-did-not-meet-primary-endpoint
FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment...
May 5, 2023 - FibroGen, Inc. (NASDAQ: FGEN) today announced that MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with...